Literature DB >> 15753659

Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion.

Rui Shi1, Liu Hong, Daocheng Wu, Xiaoxuan Ning, Yu Chen, Tao Lin, Daiming Fan, Kaichun Wu.   

Abstract

CpG oligodeoxynucleotides (CpG ODN) have been shown to have potent adjuvant activity for a wide range of antigens. Of particular interest is their improved activity when closely associated with the antigen. The purpose of this study is to construct a nanovaccine coencapsulated with a gastric cancer specific antigen MG7 mimotope peptide and adjuvant CpG ODN 1645 using new nanotechnology as nanoemulsion and evaluate its immunocompetence. Nanoemulsion vaccine was prepared using magnetic ultrasound methods. BALB/c mice were immunized and the in vivo effectiveness was evaluated using tumor challenge assay. It was shown that the tumor masses formed in the mice immunized with coencapsulated nanovaccine (0.0825 g) markedly smaller (P < 0.01) than those formed in the mice immunized with nanovaccine encapsulated with antigen peptide alone (0.4465 g). A tumor inhibiting rate as high as 82.5% of the coencapsulated nanovaccine was obtained, while nanovaccine encapsulated with peptide only could not achieve the same effect (28.5%) (P < 0.01). Enzyme-linked immunospot assay (ELISPOT) showed that immunization using MG7 mimotope peptide coencapsulated with CpG ODN within the same nanoemulsion enhanced the frequency of splenocytes secreting IFN-gamma significantly (P < 0.01) when compared with immunization using MG7 peptide encapsulated in nanoemulsion alone (197spots/1 x 10(6) vs. 73 spots/1 x 10(6)). Cellular ELISA indicated that serum titer of antibody against MG7-Ag was significantly higher (P < 0.01) in mice immunized with coencapsulation form nanovaccine (0.7884) than that in the group immunized with nanovaccine encapsulated with MG7 peptide alone (0.3616). Using intracellular flow cytometric analysis, it was found that the IFN-gamma response was contributed by CD4+ T-cells. Our experiments suggest that a vaccinal approach using nano-delivery system carrying in tumoral epitope and CpG ODN as adjuvant may have important implications for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15753659     DOI: 10.4161/cbt.4.2.1472

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  5 in total

1.  The role of toll-like receptors (TLRs) in pan-cancer.

Authors:  Runzhi Huang; Zehui Sun; Shuyuan Xian; Dianwen Song; Zhengyan Chang; Penghui Yan; Jie Zhang; Huabin Yin; Zixuan Zheng; Peng Hu; Zhenyu Li; Dan Huang; Yihan Liu; Chenyang Jiang; Man Li; Siqi Li; Tong Meng; Daoke Yang; Zongqiang Huang
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

2.  Impact of CHK2-small interfering RNA on CpG ODN7909-enhanced radiosensitivity in lung cancer A549 cells.

Authors:  Wei Chen; Xiaoqun Liu; Tiankui Qiao; Sujuan Yuan
Journal:  Onco Targets Ther       Date:  2012-12-03       Impact factor: 4.147

Review 3.  Nanoparticle delivery systems in cancer vaccines.

Authors:  Yogita Krishnamachari; Sean M Geary; Caitlin D Lemke; Aliasger K Salem
Journal:  Pharm Res       Date:  2010-08-19       Impact factor: 4.580

4.  The effect of ataxia-telangiectasia mutated kinase-dependent hyperphosphorylation of checkpoint kinase-2 on oligodeoxynucleotide 7909 containing CpG motifs-enhanced sensitivity to X-rays in human lung adenocarcinoma A549 cells.

Authors:  Xiaoqun Liu; Xiangdong Liu; Tiankui Qiao; Wei Chen; Sujuan Yuan
Journal:  Onco Targets Ther       Date:  2015-06-10       Impact factor: 4.147

5.  Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine.

Authors:  HongWu Sun; Chao Wei; BaoShuai Liu; HaiMing Jing; Qiang Feng; YaNan Tong; Yun Yang; LiuYang Yang; QianFei Zuo; Yi Zhang; QuanMing Zou; Hao Zeng
Journal:  Int J Nanomedicine       Date:  2015-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.